Approval · Notice of Compliance 37415 · 2026
PRIORIX: Notice of Compliance 37415
Issued April 27, 2026
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 37415
- Date
- April 27, 2026
- Company
- Glaxosmithkline IncMississauga, Ontario, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Additional manufacturing site
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| PRIORIX | Not yet assigned | — |
Medicinal ingredients
- MEASLES VIRUS LIVE ATTENUATED (SCHWARZ STRAIN) 1,000 CCID50 per 0.5ML
- RUBELLA VIRUS LIVE ATTENUATED (WISTAR RA 27/3 STRAIN) 1,000 CCID50 per 0.5ML
- MUMPS VIRUS LIVE ATTENUATED (RIT 4385 STRAIN) 5,011.8723 CCID50 per 0.5ML